Transforming Cancer Detection: The Power of Real-World Evidence and AI in Multi-Cancer Early Detection (MCED) Studies

Join us as we delve into the groundbreaking partnership between OM1 and Exact Sciences in the Falcon Registry Real-World Evidence (RWE) study. This ambitious initiative aims to enroll 25,000 patients across diverse backgrounds to evaluate the clinical impact of Multi-Cancer Early Detection (MCED) testing. Discover how this study leverages real-world data and advanced prospective data generation technology to advance MCED technology, improve patient outcomes, and reshape the future of cancer care. Learn about the innovative approaches used to assess the effectiveness of MCED tests, the collaboration with leading health systems, and the potential to transform early cancer detection globally.

Learning Objectives:

• – Understand the Clinical Impact of MCED Testing: Gain insights into how the Falcon Registry RWE study evaluates Multi-Cancer Early Detection (MCED) testing’s effectiveness across diverse patient populations and its potential to improve early cancer detection and patient outcomes.
• – Explore the Use of Real-World Data (RWD) and Advanced Prospective Data Generation: Learn about the innovative methodologies used to leverage real-world data and advanced prospective data collection technologies to support evidence generation in MCED testing.
• – Identify Strategies for Regulatory Collaboration: Gain insights into collaborative approaches between OM1 and Exact Sciences to align with regulatory expectations, aiming to advance MCED technology approvals and ensure compliance in global cancer detection initiatives and Real-world data submissions.

Moderator:

Eric Schrock

Chief Technology Officer and Head of Aspen Solutions

OM1

Panelist:

Vijay Parthasarathy

Vice President of Product Management, Multi-Cancer Early Detection

Exact Sciences

Panelist:

Rich Gliklich

CEO

OM1